TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07651319: Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease

Sponsor: The Methodist Hospital Research Institute · Phase: PHASE1/PHASE2 · Area: CNS_NEUROLOGY · Target Enrollment: 30 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$10,553,600

Rescue Site Savings

+$6,958,780

Unlock Full NCT07651319 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07651319 Rescue Dossier →